Melinta Therapeutics announces FDA approval of REZZAYO™
Congratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read Details
Vertex announces UK approval for CASGEVY™
Vertex announces UK approval for CASGEVY™
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
We are proud to have contributed to Vertex’s cold chain with full transport validation support, including transport simulation testing using Modality Solutions’ Advantage Transport Simulation Laboratory™.
Stay on top of the industry trends
You may also like
Iveric Bio announces FDA approval for IZERVAY™️️
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details
Incyte announces FDA approval for Zynyz™
Congratulations to Incyte on their FDA approval for Zynyz™, a treatment for adults with metastatic...
read Details